Alma, which makes software program and help instruments for psychological well being professionals constructing their practices, raised $130 million in Sequence D funding. The spherical comes a couple of yr after the corporate introduced its $50 million Series C.
The spherical was led by Thoma Bravo, with participation from Cigna Ventures, Perception Companions, Optum Ventures, Tusk Enterprise Companions, Main Enterprise Companions and Sound Ventures. Alma stated its whole increase is now greater than $220 million.
The startup affords teletherapy software program, billing and scheduling instruments and a group of different psychological healthcare professionals in addition to a listing to assist sufferers discover in-network suppliers.
“By centering therapists on the forefront, Alma is making a sustainable enterprise mannequin that helps suppliers settle for insurance coverage, develop their non-public observe, and attain extra folks searching for care. Over the previous yr, we scaled our providers to supply in-network psychological well being care in all 50 U.S. states, serving to folks discover much-needed care throughout their biggest moments of want,” Alma founder and CEO Dr. Harry Ritter stated in an announcement.
Honest Sq. Medicare, a tech-enabled insurance coverage navigator, introduced Thursday it had raised $15 million in Sequence A funding.
The spherical was led by Outline Ventures, with participation from Sluggish Ventures, YCombinator and angel buyers, and introduced the startup’s whole increase to $19 million.
With the funding, Honest Sq. Medicare plans to launch new providers, together with serving to seniors discover and schedule appointments with suppliers, establishing preventative well being and dental care, discovering lower-cost prescription choices and accessing digital continual care administration applications.
“Seniors deserve a trusted healthcare associate that is at all times appearing of their greatest curiosity,” Chirag Shah, associate at Outline Ventures, stated in an announcement. “Honest Sq. Medicare’s mannequin builds belief with seniors, as a result of it treats them like household. While you prioritize the long-term relationship with the client over potential short-term monetary positive factors, they’re going to belief you with extra of their well being. That is the recipe for sustainable progress, which is why we’re investing in Honest Sq. Medicare’s future.”
Avenda Well being, which is growing an AI platform to higher visualize prostate most cancers, scored $10 million in a Sequence B funding spherical led by VCapital.
Different individuals within the increase embody Plug & Play Ventures and Wealthing VC Membership. The startup plans to make use of the capital to hurry the usage of iQuest, its investigational software program goals to visualise most cancers for higher remedy planning.
“Our firm’s mission is to offer clinicians and their sufferers larger entry to care whereas sustaining high quality of life that’s usually lacking in prostate most cancers remedy. Our expertise is fixing key points in males’s well being and we look ahead to creating actual change in prostate most cancers care,” Avenda CEO and cofounder Dr. Shyam Natarajan stated in an announcement. “This funding will play a crucial position in increasing the aptitude and attain of our expertise, whereas including to our skilled staff of urology, medical system and AI leaders.”
Oncology medical trial startup Trial Library emerged from stealth earlier this week with $5 million in seed funding.
The spherical was led by Deena Shakir, associate at Lux Capital, with participation from Julian Eison, managing associate at NEXT VENTŪRES, Unseen Capital and different angel buyers.
The corporate affords reimbursement to native suppliers and oncology practices for pre-screening and referring sufferers to medical trials. It additionally gives navigators for sufferers seeking to enroll, directing them to journey, meals and logistics assets.
“The dearth of fairness in entry is a large barrier that must be solved,” CEO and founder Dr. Hala Borno stated in an announcement. “As a society, we have invested a lot into thrilling new biotech therapies and we’re optimistic that many of those personalised therapies will prolong sufferers’ lives. Nevertheless, there are nonetheless many obstacles that exist, and we intention to fight the obstacles skilled by all individuals in our analysis ecosystem – the sufferers, suppliers and researchers.”